The company reported positive results from its PROPEL 3 study of its experimental oral therapy, infigratinib, in children with achondroplasia, a genetic form of dwarfism.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally?
The company reported positive results from its PROPEL 3 study of its experimental oral therapy, infigratinib, in children with achondroplasia, a genetic form of dwarfism.